抗菌药物PK/PD参数对优化抗菌药物给药方案的进展

Abstract
Figure/Table
References
Related Citation (15)

[3]	Roberts J A,Norris R,Paterson D L,et al. Therapeutic drug monitoring of antimicrobials[J].Br J Clinpharmacol, 2012, 73(1):27-36.
[1]	Mouton J W, Ambrose P G,Canton R,et al. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective[J]. Drug Resist, 2011,14(2):107-117.
[4]	David andes. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance[J]. Drug Resistance Updates,2004,7(3):185-194.
[2]	Goncalves J, Povoa P .Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams[J].Critical Care,2011,15:8206.
[5]	Morita K. Optimization of antimicrobial therapy based on therapeutic drug monitoring[J].Yakugaku Zasshi, 2011, 131(10): 1407-1413.
[3]	Roberts J A,Norris R,Paterson D L,et al. Therapeutic drug monitoring of antimicrobials[J].Br J Clinpharmacol, 2012, 73(1):27-36.
[6]	Nailor M D,Chandrasekar P H.Antifungal drugs: predicting clinical efficacy with pharmacodynamics[J]. Expert Rev,2009,2(4):373-379.
[4]	David andes. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance[J]. Drug Resistance Updates,2004,7(3):185-194.
[7]	肖永红,王进,朱燕,等.Mohnarin 2008年度全国细菌耐药监测[J].中华医院感染学杂志,2010, 20(16): 2377- 2383.
[5]	Morita K. Optimization of antimicrobial therapy based on therapeutic drug monitoring[J].Yakugaku Zasshi, 2011, 131(10): 1407-1413.
[8]	Bowker K E,Garvey M I,Noel A R,et al. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculums[J]. J Antimicrob Chemother,2013,12:452.
[9]	Cook A M, Martin C, Adams V R, et al. Pharmacokinetics of Intravenous Levofloxaci Administered at 750 Milligrams in Obese Adults[J].Antirreicrob Agents and chemother,2011,55(7):3240-3243
[6]	Nailor M D,Chandrasekar P H.Antifungal drugs: predicting clinical efficacy with pharmacodynamics[J]. Expert Rev,2009,2(4):373-379.
[7]	肖永红,王进,朱燕,等.Mohnarin 2008年度全国细菌耐药监测[J].中华医院感染学杂志,2010, 20(16): 2377- 2383.
[10]	Mohd A A,Staatz C E,Kirkpatrick C M,et al. Continuous infusion vs. bolus dosing: implications for betalactam antibiotics [J]. Minerva Anestesiol,2012HYPERLINK “javascript:void(null)”,HYPERLINK “javascript:void(null)”78(1):94-104.
[8]	Bowker K E,Garvey M I,Noel A R,et al. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculums[J]. J Antimicrob Chemother,2013,12:452.
[11]	Verdier M C,Tribut O,Tattevin P,et al. Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients[J].J Chemother,2011HYPERLINK “javascript:void(null)”, HYPERLINK “javascript:void(null)”23HYPERLINK “javascript:void(null)”(HYPERLINK “javascript:void(null)”5):277-281.
[9]	Cook A M, Martin C, Adams V R, et al. Pharmacokinetics of Intravenous Levofloxaci Administered at 750 Milligrams in Obese Adults[J].Antirreicrob Agents and chemother,2011,55(7):3240-3243
[12]	杜德才,周书明,沈爱宗,等.医院抗菌药物使用强度分析[J].中华医院感染学杂志,2010 ,20 (6) :848-851.
[13]	陈领弟, 白学敏, 姜溯彭. 医院感染患者抗菌药物应用调查分析[J]. 中华医院感染学杂志 , 2012, 22(2):366-367.
[10]	Mohd A A,Staatz C E,Kirkpatrick C M,et al. Continuous infusion vs. bolus dosing: implications for betalactam antibiotics [J]. Minerva Anestesiol,2012HYPERLINK “javascript:void(null)”,HYPERLINK “javascript:void(null)”78(1):94-104.
[14]	王贺,徐英春,陈民钧.细菌质粒介导的喹诺酮类抗菌药物耐药机制研究进展[J].中华医院感染学杂志,2007,17(5):618-620.
[11]	Verdier M C,Tribut O,Tattevin P,et al. Assessment of interindividual variability of plasma concentrations after administrazion of high doses of intravenous amoxicillin or cloxacillin in critically ill patients[J].J Chemother,2011HYPERLINK “javascript:void(null)”, HYPERLINK “javascript:void(null)”23HYPERLINK “javascript:void(null)”(HYPERLINK “javascript:void(null)”5):277-281.
[15]	Textoris J, Wiramns S, Martin C, et al. Antibiotic therapy in patients with septic shock[J]. Eur J Anaesthesiol,2011,28:318-324.
[12]	杜德才,周书明,沈爱宗,等.医院抗菌药物使用强度分析[J].中华医院感染学杂志,2010 ,20 (6) :848-851.
[13]	陈领弟, 白学敏, 姜溯彭. 医院感染患者抗菌药物应用调查分析[J]. 中华医院感染学杂志 , 2012, 22(2):366-367.
[16]	American Thoracic Societv,Infectious Diseases Societv of America. Guidelines for the management of adults with hospital-acduired, ventilator-associated, and healthcare-associated pneumonia[J]. Am J Care Med, 2005, 171:388-416.
[14]	王贺,徐英春,陈民钧.细菌质粒介导的喹诺酮类抗菌药物耐药机制研究进展[J].中华医院感染学杂志,2007,17(5):618-620.
[17]	Lamoth F, Bnclin T, Csajka C, et al. Reassessment of recommended imipenem doses in febrile nentropenic patients with hematological malignancies[J]. Antimicrob Agents Chemother,2009,53:785-787.
[15]	Textoris J, Wiramns S, Martin C, et al. Antibiotic therapy in patients with septic shock[J]. Eur J Anaesthesiol,2011,28:318-324.
[18]	张波,朱珠.蒙特卡罗模拟在抗生素药动学和药效学中的应用[J].中国药学杂志,2008,43 (4):241-244.
[19]	Doh K,Woo H,Hur J et al. Population pharmacokinetics of meropenem in burn patients[J]. J Antimicrob Chemother, 2010, 65(11): 2428-2435.
[16]	American Thoracic Societv,Infectious Diseases Societv of America. Guidelines for the management of adults with hospital-acduired, ventilator-associated, and healthcare-associated pneumonia[J]. Am J Care Med, 2005, 171:388-416.
[20]	Du X, Li C, Kuti J L, et al. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients [J]. J Clin Pharmacol, 2006, 46(1):69-75.
[17]	Lamoth F, Bnclin T, Csajka C, et al. Reassessment of recommended imipenem doses in febrile nentropenic patients with hematological malignancies[J]. Antimicrob Agents Chemother,2009,53:785-787.
[18]	张波,朱珠.蒙特卡罗模拟在抗生素药动学和药效学中的应用[J].中国药学杂志,2008,43 (4):241-244.
[21]	Moslemi M K,Movahed S M,Heidari A , et al. Comparative evaluation of prophylactic; single-dose intravenous antibiotic; with postoperative antibiotic、in elective urologicsurgery[J]. Ther Clin Risk Manag, 2010,9 (6):551-556.
[19]	Doh K,Woo H,Hur J et al. Population pharmacokinetics of meropenem in burn patients[J]. J Antimicrob Chemother, 2010, 65(11): 2428-2435.
[20]	Du X, Li C, Kuti J L, et al. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients [J]. J Clin Pharmacol, 2006, 46(1):69-75.
[21]	Moslemi M K,Movahed S M,Heidari A , et al. Comparative evaluation of prophylactic; single-dose intravenous antibiotic; with postoperative antibiotic、in elective urologicsurgery[J]. Ther Clin Risk Manag, 2010,9 (6):551-556.